Last updated: May 14, 2026
What is LINCOCIN and what active ingredient and forms does it cover?
LINCOCIN is a brand name for lincomycin, an older lincosamide antibiotic used for susceptible bacterial infections. It is typically supplied as oral capsules and parenteral formulations (products and strengths vary by market and manufacturer). LINCOCIN is generally positioned in the antibiotics space rather than a high-growth specialty segment.
Which regulators and products are typically tied to LINCOCIN?
Lincomycin products are commonly associated with legacy approvals and ongoing generic competition. Product availability and labeling depend on jurisdiction, and brand continuity can vary as markets move through NDC changes, manufacturer transitions, and generic substitutions.
What clinical trials for lincomycin/LINCOCIN are active, completed, or recruiting?
No complete, current, verifiable clinical-trials dataset for “LINCOCIN” or lincomycin bearing that brand name is available in the provided information. A trials update requires a specific queryable source such as ClinicalTrials.gov (NCT records), EU Clinical Trials Register, or published trial registers, plus trial status and dates. Without that, a complete and accurate “clinical trials update” cannot be produced.
How big is the lincomycin (LINCOCIN) market and what drives demand?
Demand is driven by:
- Narrower modern use versus newer antibiotics, with lincomycin often used when first-line beta-lactams or other options are unsuitable.
- Formulary and local susceptibility patterns in targeted infections.
- Supply continuity and pricing dynamics as brands face generic substitution.
- Institutional prescribing protocols and stewardship policies that restrict older agents.
Market profile:
- Lower growth than anti-infectives with newer mechanisms.
- Higher sensitivity to generic price erosion.
- Limited blockbuster upside given the age of the agent and the availability of alternatives.
What is the competitive landscape for LINCOCIN (lincomycin) including generics and substitutes?
Competitive set typically includes:
- Generic lincomycin products in oral and injectable formats (where marketed).
- Therapeutic substitutes within anti-infectives, including other lincosamides such as clindamycin (often preferred in practice), plus broader-spectrum antibiotic classes depending on infection type and resistance patterns.
Where does clindamycin displace lincomycin?
Clindamycin is a common alternative when clinicians choose the lincosamide class, which can reduce brand-level share for lincomycin in many markets where clindamycin is easier to source or favored on formulary.
When does LINCOCIN lose exclusivity and what is the generic entry risk?
A credible exclusivity and generic-entry assessment requires:
- the specific FDA NDA/ANDA or legacy application number for the LINCOCIN brand,
- Orange Book listing details for active/inactive ingredients and specific dosage forms,
- and patent term or exclusivity end dates per listing.
No such Orange Book linkage or application identifier is provided in the prompt. Without it, exclusivity loss timing and Paragraph IV risk cannot be stated accurately.
What patents protect lincomycin/LINCOCIN and how strong is the patent estate?
Patent strength and coverage depend on the exact application and jurisdiction. For legacy antibiotics, patent estates are often thin or expired, but a correct analysis requires:
- a complete patent list tied to the specific marketed product(s),
- jurisdictional expiration dates,
- and any ongoing litigation or regulatory stays.
No patent estate data is provided, so the assessment cannot be completed without risking incorrect facts.
What is the Orange Book status of LINCOCIN?
Orange Book status requires an explicit product match via drug name, dosage form, and applicant holder. No Orange Book listing record is provided. A full status statement (listed patents, expiration dates, exclusivities) cannot be produced from the input.
What is the FDA regulatory pathway and approval history for LINCOCIN?
A complete regulatory pathway narrative requires the specific FDA application (NDA/ANDA) and labeling history. No application numbers, approval dates, or manufacturing changes are included, so pathway and lifecycle status cannot be stated.
How does LINCOCIN compare with clindamycin and other lincosamides on clinical use and market share?
High-level comparison:
- Clinical preference: clindamycin is frequently used over lincomycin in practice due to broader availability and clinician familiarity.
- Market effect: clindamycin’s market presence can cap lincomycin’s share even if lincomycin remains available for certain indications.
A precise, decision-grade market-share comparison needs sales data (IMS/National accounts or audited sources) and specific formulary penetration, none of which is included.
Market projection for LINCOCIN through 2030: base, upside, downside
A numerical projection requires a starting point (revenue or unit sales), baseline growth rate, expected generic penetration schedule, and competitive/price assumptions. None of these inputs are provided in the prompt, and no source dataset is available here. As a result, a complete projection cannot be produced without inventing figures.
Key Takeaways
- LINCOCIN is a brand for lincomycin, an older lincosamide antibiotic.
- A clinical trials update cannot be completed without a verifiable trial register dataset tied to LINCOCIN/lincomycin and current statuses.
- Market sizing and projections cannot be stated accurately without a starting revenue or unit basis and a specific product listing context (region, NDC, formulation, sales channel).
- Exclusivity, Orange Book status, and patent estate analysis requires specific application and listing identifiers that are not included.
FAQs
- What is the current clinical role of lincomycin in infections compared with clindamycin?
- How do generic lincomycin formulations typically differ from branded LINCOCIN in absorption and dosing guidance?
- What are the most common resistance and stewardship constraints affecting lincomycin prescribing today?
- How do injectable supply constraints impact availability and substitution to other antibiotics?
- What regulatory signals (label changes, shortages, recalls) most often move lincomycin brand utilization?
References
No sources were cited because no verifiable clinical trials, Orange Book listings, patent records, or market datasets were provided in the prompt.
